On August 10, 2023, PROPHASE LABS ($NASDAQ:PRPH) reported their earnings results for the second quarter of the 2023 fiscal year (ending June 30, 2023). Total revenue saw a decrease of 54.6% compared to the same quarter of the previous year, amounting to USD 13.2 million. Net income for the quarter was recorded to be USD -3.4 million, compared to a net income of 7.4 million in the same quarter of the prior year.
On the same day, the company’s stock opened at $6.8 and closed at $6.3, which was a 9.9% drop from its last closing price of $7.0. This decrease in the stock price was likely due to the fact that PROPHASE LABS‘ earnings report was not as strong as investors and analysts had anticipated. The report showed that the company had not made as much progress in its current projects and initiatives as expected. Additionally, there were some financial issues that the company had to tackle as well, such as higher operating costs that could negatively impact their profits going forward.
However, despite these challenges, PROPHASE LABS is still optimistic about its future growth and is looking forward to the third quarter of fiscal year 2023. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Prophase Labs. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Prophase Labs. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Prophase Labs. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Prophase Labs are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we believe it is important to take an informed approach to investing. That’s why we’ve taken a closer look at PROPHASE LABS in order to give investors a better understanding of the company and its underlying fundamentals. After conducting an analysis of the company, we have assigned PROPHASE LABS a medium risk rating. This indicates that there are potentially some risks associated with the business, but they are manageable and should not deter investors from investing if they are confident in their decision. We have also detected two risk warnings in PROPHASE LABS’ income and balance sheets. If you would like to see exactly what these warnings are and how they may affect your investment decision, then please register for free on our website. With GoodWhale’s help, you can be sure that you’re making an informed decision when it comes to investing in PROPHASE LABS. More…
Risk Rating Analysis
Star Chart Analysis
ProPhase Labs Inc is a leading provider of probiotics and other health supplements. Its main competitors are Probi AB, Mizuho Medy Co Ltd, and Goodbody Health Inc. All three companies offer similar products and services, but ProPhase Labs Inc has a competitive advantage in terms of its probiotic offerings.
Probi AB is a Swedish biotech company that specializes in the development of probiotics. The company was founded in 1991 and has since then been a pioneer in the probiotics industry. Probi’s products are based on live bacteria that are beneficial for human health, and they are sold in over 40 countries worldwide.
Probi’s market cap is 2.38 billion as of 2022, and its return on equity is 5.99%. The company’s strong financial position and proven track record make it a well-respected player in the probiotics industry.
– Mizuho Medy Co Ltd ($TSE:4595)
Mizuho Medy Co Ltd is a pharmaceutical company with a market cap of 28.48B as of 2022. The company has a Return on Equity of 53.42%. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company’s products are sold in over 60 countries.
Goodbody Health Inc is a healthcare company that provides services to patients and families. The company has a market cap of 5.33M and a ROE of -7.21%. The company’s main products and services include: medical and surgical services, home health services, and hospice services. Goodbody Health Inc operates in the United States and Canada.
PROPHASE LABS reported total revenue of USD 13.2 million for its second quarter of fiscal year 2023, a decrease of 54.6% from the same quarter last year. Net income was reported as USD -3.4 million, a drop from the previous year’s USD 7.4 million. The company’s stock price fell on the same day as the earnings announcement, indicating investors are not enthusiastic about its short-term prospects.
As such, it may be wise for investors to exercise caution if considering investing in PROPHASE LABS in the near future. Investors may wish to look further into the company’s financials and strategize accordingly before making any decisions.